Clinical Trials Logo

Clinical Trial Summary

To provide Omegaven® as a compassionate treatment for critically ill infants with parenteral nutrition associated cholestasis


Clinical Trial Description

An intermediate population, Investigational New Drug study, to provide an alternate intravenous fat nutrition, Omegaven®, to help improve liver function while providing adequate nutrition for critically ill infants with parenteral nutrition associated cholestasis ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03662282
Study type Interventional
Source University of South Florida
Contact
Status Completed
Phase Phase 3
Start date October 23, 2018
Completion date January 7, 2019

See also
  Status Clinical Trial Phase
Completed NCT04510090 - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus Phase 1
Completed NCT02917408 - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Completed NCT00738101 - Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants N/A
Completed NCT00004414 - Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis N/A
Recruiting NCT02334293 - Omegaven® as Parenteral Nutrition N/A
Recruiting NCT01252043 - Retrospective Review of CT and MR in Pediatric Patients With Cholestasis N/A
Completed NCT00846963 - Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates Phase 2/Phase 3
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Completed NCT01194063 - Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children Phase 3
Recruiting NCT01998620 - Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Phase 4
Completed NCT00080236 - Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation Phase 2
Completed NCT00058890 - Gabapentin to Treat Itch in Patients With Liver Disease Phase 3
Active, not recruiting NCT00004315 - Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease Phase 2
Active, not recruiting NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Completed NCT04604652 - Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis Phase 2
Terminated NCT02267707 - Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia Phase 1
Completed NCT02357576 - Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD Phase 3
Completed NCT02721277 - SMOFlipid to Lessen the Severity of Neonatal Cholestasis Phase 1/Phase 2
Terminated NCT02767648 - Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region N/A
Completed NCT01073202 - Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation N/A